PDX models of human lung squamous cell carcinoma: Consideration of factors in preclinical and co-clinical applications

Hae Yun Jung, Tae Ho Kim, Jong Eun Lee, Hong Kwan Kim, Jong Ho Cho, Yong Soo Choi, Sumin Shin, Se Hoon Lee, Hwanseok Rhee, Hee Kyung Lee, Hyun Jung Choi, Hye Yoon Jang, Seungjae Lee, Jung Hee Kang, Young Ae Choi, Sanghyuk Lee, Jinseon Lee, Yoon La Choi, Jhingook Kim

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background: Treatment of human lung squamous cell carcinoma (LUSC) using current targeted therapies is limited because of their diverse somatic mutations without any specific dominant driver mutations. These mutational diversities preventing the use of common targeted therapies or the combination of available therapeutic modalities would require a preclinical animal model of this tumor to acquire improved clinical responses. Patient-derived xenograft (PDX) models have been recognized as a potentially useful preclinical model for personalized precision medicine. However, whether the use of LUSC PDX models would be appropriate enough for clinical application is still controversial. Methods: In the process of developing PDX models from Korean patients with LUSC, the authors investigated the factors influencing the successful initial engraftment of tumors in NOD scid gamma mice and the retainability of the pathological and genomic characteristics of the parental patient tumors in PDX tumors. Conclusions: The authors have developed 62 LUSC PDX models that retained the pathological and genomic features of parental patient tumors, which could be used in preclinical and co-clinical studies. Trial registration Tumor samples were obtained from 139 patients with LUSC between November 2014 and January 2019. All the patients provided signed informed consents.

Original languageEnglish
Article number307
JournalJournal of Translational Medicine
Issue number1
StatePublished - 6 Aug 2020

Bibliographical note

Publisher Copyright:
© 2020 The Author(s).


  • Engraftment
  • Lung squamous cell carcinoma
  • Patient-derived xenograft
  • Preclinical model
  • Xenograft-associated lymphoproliferative disease


Dive into the research topics of 'PDX models of human lung squamous cell carcinoma: Consideration of factors in preclinical and co-clinical applications'. Together they form a unique fingerprint.

Cite this